文献速递主动脉疾病颈动脉与弓上血管

开窗腔内修复治疗累及主动脉弓的疾病

Fenestrated endovascular repair for diseases involving the aortic arch.
PubMed 文献 · J Vasc Surg · 2020-02-13

单中心回顾性分析2011至2017年44例采用定制开窗支架治疗主动脉弓疾病患者,技术成功率95%,30天死亡率9%,主要卒中7%,临时脊髓缺血7%。随访期间10例需二次干预,多为计划性远端干预以完成胸腹主动脉病变修复。

要点

  • 开窗腔内修复治疗主动脉弓疾病技术成功率高,卒中与截瘫发生率可接受。
  • 术后常需二次干预以完成胸腹主动脉病变的全程修复。
  • 近端锚定区位于Ishimaru 0–2区,需个体化设计开窗或扇形凹槽。

核心结论

  • 开窗腔内修复治疗主动脉弓疾病可行,技术成功率高,卒中与截瘫发生率可接受,但常需二次干预完成基础疾病治疗。

研究设计与样本

  • 单中心前瞻性收集数据的回顾性分析,纳入2011至2017年连续44例采用定制开窗支架(Cook Medical)治疗主动脉弓疾病的患者。

主要发现

  • 44例患者平均年龄67±9岁,男性27例(61%)。
  • 病变包括弓部动脉瘤11例(25%)、弓部穿透性动脉溃疡6例(14%)、累及弓部的胸腹主动脉瘤11例(25%)、夹层后假腔动脉瘤13例(29%)、Lusorian动脉瘤3例(7%)。
  • 近端锚定区Ishimaru 0区12例(27%)、1区27例(62%)、2区5例(11%)。
  • 技术成功率95%(42/44),30天死亡率9%(4/44),主要卒中3例(7%),临时脊髓缺血3例(7%),肾损伤3例(7%),早期再干预3例(7%)。
  • 平均随访18±17个月,10例需二次干预,其中90%为计划性远端干预;术后1年与2年总生存率分别为78%±7%和72%±8%。

临床怎么用

  • 对于累及主动脉弓的高危患者,开窗腔内修复可作为维持弓上分支通畅的替代方案。
  • 术前需根据Ishimaru分区个体化设计开窗或扇形凹槽,并计划必要的颈动脉-锁骨下动脉旁路或锁骨下动脉转位。
  • 术后需长期随访,部分患者需计划性二次干预以完成胸腹主动脉病变修复。

局限性

  • 单中心回顾性研究,样本量44例,随访时间平均18±17个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Extension of aortic disease to the aortic arch is common, frequently requiring cervical debranching procedures to maintain patency of supra-aortic branches. Endovascular aortic arch repair is an attractive alternative in the treatment of aortic arch disease for high-risk patients with thoracoabdominal diseases encroaching on the arch. The aim of our study was to report our experience of fenestrated endovascular repair in the aortic arch. METHODS: A retrospective review of prospectively collected data involving consecutive patients in a single tertiary center treated with custom-made fenestrated endografts for the aortic arch (Cook Medical, Bloomington, Ind) was undertaken. End points included technical success, perioperative mortality and morbidity, reintervention, and late survival. RESULTS: Between 2011 and 2017, there were 44 patients with a mean age of 67 ± 9 years (27 male [61%]) who were treated with fenestrated endografts for arch aneurysm (n = 11 [25%]), arch penetrating aortic ulcer (n = 6 [14%]), thoracoabdominal aneurysm with arch involvement (n = 11 [25%]), postdissection false lumen aneurysm (n = 13 [29%]), or lusorian artery aneurysm (n = 3 [7%]). The proximal landing zone was at Ishimaru zone 0 in 12 cases (27%), zone 1 in 27 cases (62%), and zone 2 in 5 cases (11%). Nine patients (20%) underwent a unilateral carotid-subclavian bypass, two (5%) a bilateral carotid-subclavian bypass, and four (9%) a subclavian transposition. In total, of the 73 target supra-aortic vessels (average of 1.7 target vessels per patient), 37 were treated with fenestrations and 36 with scallops. The mean operation time, fluoroscopy time, and contrast material volume were 215 ± 152 minutes, 33 ± 23 minutes, and 114 ± 45 mL, respectively. Technical success was 95% (42/44). The median intensive care unit and hospital stays were 3 ± 1 days and 7 ± 6 days, respectively. The 30-day mortality was 9% (4/44; one graft displacement and stroke, one retrograde type A dissection, one access complication and stroke, and one death of unknown cause). Major stroke occurred in three (7%), minor stroke in one (2%), temporary spinal cord ischemia in three (7%), and renal injury in three (7%) patients, whereas three (7%) patients required early reintervention. With mean follow-up of 18 ± 17 months, 10 more patients required secondary interventions, most of which (90%) were planned distal intervention to complete the repair of thoracoabdominal diseases. Overall survival rates were 78% ± 7% and 72% ± 8% at postoperative years 1 and 2, respectively. CONCLUSIONS: Fenestrated endograft repair of aortic arch disease is a feasible technique with a high technical success rate and acceptable rates of stroke and paraplegia. A high number of secondary interventions were needed to complete the treatment of underlying diseases.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tsilimparis N, Law Y, Rohlffs F, et al. Fenestrated endovascular repair for diseases involving the aortic arch. J Vasc Surg. 2020. PMID: 32063444. doi:10.1016/j.jvs.2019.06.205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。